Akebia Therapeutics (AKBA) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Akebia Therapeutics (AKBA) has outperformed Organogenesis (ORGO) over the past year, losing 75.1% versus a loss of 86.2%. Over five years, AKBA leads with a -85.6% price change compared with -92.2% for ORGO. Akebia Therapeutics is the larger company by market cap ($107.0 million vs $100.2 million), about 1.1 times the size.
Organogenesis converts more of its revenue into profit, with a net margin of 6.6% versus -2.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | ORGO |
|---|---|---|
| Share price | $0.3855 | $0.7716 |
| Market cap | $107.04M | $100.16M |
| 1-day change | -8.71% | -2.23% |
| YTD return | -76.06% | -85.10% |
| 1-year return | -75.13% | -86.20% |
| 5-year return | -85.56% | -92.25% |
| EPS (TTM) | $-0.17 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | $564.17M |
| Revenue growth (YoY) | +47.46% | +17.04% |
| Net income (latest FY) | $-5.34M | $37.03M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | 7.92% |
| Net margin | -2.26% | 6.56% |
| 52-week high | $1.73 | $5.91 |
| 52-week low | $0.361 | $0.73 |
| Distance from 52-week high | -77.72% | -86.93% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +678.21% | — |
| Average volume | 8.05M | 850.26K |
| Shares outstanding | 277.66M | 129.80M |
| Employees | 194 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKBA has outperformed ORGO by 11.1 percentage points over the past year.
- Organogenesis is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -2.3 cents for Akebia Therapeutics.
- Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs +17.04%).
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
AKBA vs ORGO FAQ
Which is bigger, Akebia Therapeutics or Organogenesis?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $107.04M compared with $100.16M for Organogenesis (ORGO).
Which stock has performed better over the past year, AKBA or ORGO?
AKBA returned -75.13% over the past 12 months, compared with -86.20% for ORGO (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Organogenesis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.